The pipeline for fundamental biology research is much longer and more complex compared to pure tech. This is the reason why there are so many fewer bio-tech start-ups. The same can be said about hardware vs software in pure tech. There must be 100x start-ups in software, compared to hardware. The greatest hope for more break-thrus that can be commercialised is an increase in gov't research funding (say: 10x) and/or the gov't offering bounties with guaranteed contracts for commercial products. Example: If you can create a malaria vaccine with 75% efficacy for children under 12, then US/EU/Japan/UN will guarantee an order for 25B USD or 1B doses. (Something enormous, to really move the needle.)

Wiki tells me that she started publishing about mRNA in 2005. The first mRNA vaccine was not approved until Dec 2022. That kind of timeline is impossible for private investment to fund. It needs to come from gov'ts and non-profits.